FTRK — Fast Track Group

8-K · 8.01 !! High

Oncolytics Biotech Inc. -- 8-K 8.01: Material Event / Announcement

Oncolytics Biotech disclosed a material announcement via press release, though the specific details require reviewing the attached exhibit to understand the event's impact on shareholders.

May 4

8-K · 8.01 !! High

Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement

Cabaletta Bio will present data from its RESET-PV trial showing rese-cel efficacy in refractory pemphigus vulgaris patients without preconditioning chemotherapy, potentially simplifying treatment and reducing toxicity.

May 4

8-K

Kymera Therapeutics, Inc. -- 8-K Filing

Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.

Apr 30

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

FDA Fast Track designation for imdusiran accelerates hepatitis B development timeline and potential market entry, improving commercialization prospects and de-risking the program for shareholders.

Apr 15

8-K

Unknown — 8-K Filing

Aligos' Fast Track Designation accelerates pevifoscorvir's FDA pathway for hepatitis B, potentially enabling faster approvals and earlier revenue generation if efficacy data proves compelling in ongoing trials.

Apr 14

8-K

Unknown — 8-K Filing

I cannot provide meaningful analysis based on this fragment, as it only contains boilerplate disclaimer language about forward-looking statements with no substantive business information disclosed.

Apr 8

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Oncolytics Biotech (ONCY) may advance pelareorep toward FDA approval for anal cancer, potentially opening a new revenue stream if the pivotal trial succeeds and regulators accept the single-arm study design.

Apr 6

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Cocrystal disclosed material information via Regulation FD, suggesting significant news requiring immediate public disclosure that could materially impact the stock price and investor decisions.

Apr 2

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Context Therapeutics filed an 8-K on April 2, 2026, indicating a material event requiring disclosure, though specific details are unavailable; investors should monitor for subsequent filings clarifying the announcement's business impact.

Apr 2

8-K

Unknown — 8-K Filing

Allarity's FDA Fast Track designation for stenoparib accelerates potential approval timelines and validates clinical efficacy, reducing development risk and increasing probability of market success for this dual-mechanism cancer drug.

Apr 1

8-K

Unknown — 8-K Filing

Cadrenal Therapeutics filed an 8-K with a press release, signaling a material corporate announcement that could impact stock price; investors should review the full press release details to assess the announcement's significance.

Mar 31

8-K

Unknown — 8-K Filing

Akoustis' IND clearance for AKY-2519 Phase 1b trial removes regulatory hurdles and validates the radiopharmaceutical candidate's potential, likely attracting investor interest despite clinical-stage risk.

Mar 30

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

# Analysis: FTRK, MPLT Companies disclosed material information via press release and presentation on March 26, 2026, signaling potential earnings catalyst or strategic announcement—investors should review exhibits for specifics on forward guidance or operational developments affecting valuations.

Mar 26

8-K

Unknown — 8-K Filing

Quoin Pharmaceuticals secured $104.5M in funding and obtained Fast Track designation for QRX003, accelerating development of a rare disease treatment and improving path to commercialization, which should reduce dilution risk and increase probability of clinical success for investors.

Mar 26

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Incannex's sleep medicine partnership enhances clinical credibility and research relationships, potentially accelerating recruitment for sleep apnea trials while building institutional goodwill ahead of product development milestones.

Mar 25

8-K

Unknown — 8-K Filing

ProMIS reported 2025 financial results and corporate updates as a clinical-stage biotech, so investors should monitor cash runway, pipeline progress on neurodegenerative disease antibody candidates, and upcoming clinical trial milestones affecting stock volatility.

Mar 25

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Armata Pharmaceuticals disclosed material information via 8-K filing on March 19, 2026, though specific details aren't provided—investors should review the full disclosure to assess impact on clinical progress, partnerships, or financial position.

Mar 19

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Incannex's $75 million cash position with zero debt provides substantial runway to complete IHL-42X Phase 2 studies and fund Phase 3, reducing financing risk and dilution concerns for shareholders.

Mar 18

8-K

Unknown — 8-K Filing

Alto Neuroscience's strong financial position and advancing neuropsychiatric pipeline entering 2026 suggests reduced near-term dilution risk, potentially supporting stock valuation for clinical-stage investors betting on therapeutic progress.

Mar 16

8-K

Unknown — 8-K Filing

Lyell's Phase 3 trial of ronde-cel versus competitor CAR-T therapies represents a pivotal commercialization milestone that could validate differentiation and significantly expand addressable market if successful.

Mar 12

8-K

Unknown — 8-K Filing

Adicet's strong Phase 1 enrollment and positive autoimmune therapy data suggest clinical progress that could accelerate pipeline advancement and reduce development risk, making the stock attractive for investors betting on gamma delta T-cell therapy success.

Mar 12

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

FTRK's drug received FDA Fast Track Designation, enabling expedited development and review that could accelerate market entry, potentially generating revenue sooner and reducing development risk for investors.

Mar 11

8-K

Unknown — 8-K Filing

Artiva Biotherapeutics expects near-term catalysts—AlloNK clinical data and FDA pivotal trial guidance in H1 2026—that could validate its rheumatoid arthritis strategy and drive significant stock appreciation if successful.

Mar 10

8-K

Unknown — 8-K Filing

Taravant's clinical progress and anticipated 2026 milestones suggest potential catalysts for value creation, but investors should await actual regulatory approvals or trial data before committing capital to this cash-burning biotech.

Mar 10

8-K

Unknown — 8-K Filing

Cullinan Therapeutics has sufficient cash ($439M runway through 2029) to reach multiple clinical milestones in 2026, reducing near-term financing risk and supporting stock stability despite ongoing development timelines.

Mar 10